



**BioMarker
STRATEGIES**

News Release

Contact:

Jerry Parrott, President & CEO

301-938-4043 Mobile

iparrott@biomarkerstrategies.com

FOR IMMEDIATE RELEASE

January 6, 2020

**BioMarker Strategies to Present at Biotech Showcase 2020 in San Francisco
During J.P. Morgan Healthcare Conference Week**

*Will also Participate in BIO One on One Partnering at JPM,
and in the Life Science Nation's RESI San Francisco Conference*

Rockville, MD – January 6, 2020 – BioMarker Strategies, LLC, a company focused on helping make precision medicine more of a reality for patients with solid tumor cancers, today announced that President and CEO Jerry Parrott will present at Biotech Showcase on Wednesday, January 15 at 10:15 AM PST. The presentation will take place in Franciscan C, Ballroom Level, Hilton San Francisco Union Square.

Mr. Parrott will also participate in the Life Sciences Nation's RESI at San Francisco conference, which takes place on Tuesday January 14 at the Marines' Memorial Club & Hotel, and in the BIO One on One Partnering at JPM program, which is organized by the Biotechnology Innovation Industry (BIO), with meeting space available at the San Francisco Marriott Marquis.

These events take place in parallel to the annual J.P. Morgan Healthcare Conference, which is the largest healthcare investment symposium in the industry with more than 9,000 attendees. Other biotechnology, pharmaceutical and life sciences events, including the ones mentioned above, have been also been attracted to San Francisco for what has come to be known to many as JPM Week. For many biotechnology, pharmaceutical and life sciences companies, fund-raising and business development efforts for each year begin with JPM week.

BioMarker Strategies has developed the patented SnapPath® Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for solid tumors. SnapPath is the only diagnostics system that can generate purified populations of live solid tumor cells from live, unfixed samples in an automated and standardized manner. The system preserves the molecular integrity of these living cells for *ex vivo* exposure to immunotherapies and targeted therapies, either alone or in combination. This enables the generation of PathMap® Functional Signaling Profiles, which are highly predictive tests for assessing individual solid tumor response

to these treatments, because they are based on the dynamic, predictive signaling information available only from live cells.

About BioMarker Strategies

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Maryland. The Company's mission is to help make precision medicine more of a reality for patients with solid tumor cancers, by providing powerful new molecular tools and research services to guide targeted drug development and treatment selection for these patients. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.

Forward-Looking Statements

The information in this press release includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here.

###